Humacyte HUMA
NASDAQ HUMA
$0.52 +0.02 (+4.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Humacyte (HUMA) Return on Equity [ROE] (2021 - 2026)

Updated

Humacyte (HUMA) reported Return on Equity [ROE] of -557.97% for Q2 2026, up 33.05 percentage points from -591.02% a year earlier and up 1100.27 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) Return on Equity [ROE] (2021 - 2026) Analysis & Trends

For FY2023, Humacyte posted Return on Equity [ROE] of -155.09%, down 81.34 percentage points from FY2022.

  • By year, Return on Equity [ROE] came in at -73.75% in FY2022.
  • The Q2 2026 figure ranks as the highest quarterly Return on Equity [ROE] since Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 25.32%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 84.40%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 21.39%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 83.75%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -18.38%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.97%
10 Humacyte 144.46 Mn 144.46 Mn -825,000.00 -557.97%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -557.97%
Mar 31, 2026 -1,658.24%
Jun 30, 2025 -591.02%
Mar 31, 2024 -532.99%
Dec 31, 2023 -400.26%
Sep 30, 2023 -194.56%
Jun 30, 2023 -132.83%
Mar 31, 2023 -88.25%
Dec 31, 2022 -74.87%
Sep 30, 2022 -69.11%
Jun 30, 2022 -79.20%
Mar 31, 2022 -86.91%
Dec 31, 2021 -96.29%
API Access

Humacyte Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=HUMA&period=max&api_key=YOUR_API_KEY